Skip to main content
search

Strategic Leadership

Sign up

Latest resources

Featured resource

Certara to Participate in Upcoming Investor Conferences
Certara to Participate in Upcoming Investor ConferencesPress Release

Certara to Participate in Upcoming Investor Conferences

RADNOR, PA — April 29, 2025 -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will…

Category / type

SEND V4.0 – What to Expect and When to Expect It
SEND V4.0 – What to Expect and When to Expect ItBlog

SEND V4.0 – What to Expect and When to Expect It

April 24, 2025 As the Standard for Exchange of Nonclinical Data (SEND) continues to evolve in both scope and complexity, the upcoming release of…
Protect Confidential Information in Investigational Drug Submissions
Protect Confidential Information in Investigational Drug SubmissionsBlog

Protect Confidential Information in Investigational Drug Submissions

March 20, 2025 Health regulatory agencies require pharmaceutical companies to protect study participants’ personal information (PI) within regulatory drug submissions.…
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding studyPublication

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety, antiviral activity, and pharmacokinetics of…
Anonymization vs. Redaction of Clinical Trial Data
Anonymization vs. Redaction of Clinical Trial DataBlog

Anonymization vs. Redaction of Clinical Trial Data

January 17, 2025 The vernacular for disclosing pharmaceutical clinical trial results to the public may seem just as confusing as…

Popular resources

Certara to Participate in Upcoming Investor Conferences
Certara to Participate in Upcoming Investor ConferencesPress Release

Certara to Participate in Upcoming Investor Conferences

Certara Announces Second Annual Certainty U.S. Event
Certara Announces Second Annual Certainty U.S. EventAnnouncement

Certara Announces Second Annual Certainty U.S. Event

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal TestingPress Release

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

Certara Reports Preliminary First Quarter 2025 Financial Results Announces $100 Million Share Repurchase Authorization
Certara Reports Preliminary First Quarter 2025 Financial Results Announces $100 Million Share Repurchase AuthorizationPress Release

Certara Reports Preliminary First Quarter 2025 Financial Results Announces $100 Million Share Repurchase Authorization

Introducing the new Certara.com: Transforming drug development for good, together.
Introducing the new Certara.com: Transforming drug development for good, together.Blog

Introducing the new Certara.com: Transforming drug development for good, together.

Certara & A2Healthcare accelerate Model-informed Drug Development (MIDD) adoption in Japan
Certara & A2Healthcare accelerate Model-informed Drug Development (MIDD) adoption in JapanAnnouncement

Certara & A2Healthcare accelerate Model-informed Drug Development (MIDD) adoption in Japan

All resources heading

Sign up to newsletter

Why sign up? Because transforming drug development is not just our goal—it’s our obsession. If it’s yours too, then be the first to know of new insights and join us in pushing the boundaries of science.